A lentiviral vector is an engineered virus particle that delivers genetic instructions into cells, and in most designs those instructions are inserted into a chromosome. Getting in, being inserted, making protein and doing the intended job are four separate claims.
Common lentiviral vectors package an RNA genome. After entry the RNA is reverse-transcribed into DNA, and in an integrating design the enzyme integrase helps insert that DNA into the cell's chromosomes, where an internal promoter can drive the encoded protein. The envelope proteins influence which cells the particle enters; changing the envelope changes delivery, not what an encoded receptor recognises.
Three design labels are easy to confuse. Replication-defective means the delivered particle lacks the machinery to propagate as an ordinary virus, which does not replace testing: FDA guidance sets out testing of retroviral vector products, lentiviral ones included, for replication-competent virus during manufacture and in patient follow-up. Self-inactivating means regulatory sequences in the long terminal repeats are disabled: in the original design a 133 base-pair deletion in the U3 region of the 3' repeat was copied to the 5' repeat after reverse transcription and integration, and the vector still expressed from an internal promoter in rat brain and eye (Miyoshi and colleagues). It does not mean the cassette cannot integrate. Integration-deficient means integrase is mutated: with a class 1 integrase mutation, residual integration was lower than with intact integrase by a factor of 500 to 1,250, expression was transient in dividing cell lines and long-lived in non-dividing neural cultures and in mouse brain, consistent with an episomal genome (Philippe and colleagues). The name does not promise zero integration or lasting expression in dividing cells such as T cells.
The foundational HIV-based design transduced HeLa cells and rat fibroblasts blocked in the cell cycle and primary human macrophages, and gave stable gene transfer into terminally differentiated neurons in vivo (Naldini and colleagues; abstract read). FDA follow-up guidance notes that the activity of retroviral vectors, lentiviral ones included, comes from an integration event that is generally not directed to specific genomic sites, which raises the possibility of disrupting important genes; the risk depends on the whole product and cells.
In clinical use, third-generation self-inactivating vectors disrupt the promoter and enhancer activity of the long terminal repeat, non-integrating vectors lacking integrase have been investigated to avoid insertional mutagenesis, and recombination during manufacture could in theory produce replication-competent retrovirus or lentivirus, which is why lots are tested (Milone and O'Doherty, review).
Measurement keeps layers apart. For CAR T products FDA recommends testing vector lots for transducing units per millilitre in a suitable cell line or healthy donor cells, and reporting vector copy number, the average number of integrations per CAR-positive cell; dividing by all cells, including CAR-negative ones, lowers the reported figure, so the denominator has to be stated (FDA, January 2024). Particle or genome counts, a functional titre, copies per cell, receptor-positive percentage and antigen-dependent activity answer different questions, a particle can be counted yet not transduce, and an average copy number does not show each cell's copy number or insertion sites. These are laboratory, animal and regulatory sources, not evidence of benefit in cancer.
Showing the technology this term belongs to: Viral vector manufacturing (lentiviral, retroviral, AAV).
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares Viral vector manufacturing (lentiviral, retroviral, AAV), Autologous CAR-T manufacturing, batch by batch.
Shares Autologous CAR-T manufacturing, batch by batch, In vivo CAR-T.
Shares Autologous CAR-T manufacturing, batch by batch, In vivo CAR-T.
Shares Viral vector manufacturing (lentiviral, retroviral, AAV), Autologous CAR-T manufacturing, batch by batch.
Shares Viral vector manufacturing (lentiviral, retroviral, AAV), Autologous CAR-T manufacturing, batch by batch.
Shares Viral vector manufacturing (lentiviral, retroviral, AAV), Autologous CAR-T manufacturing, batch by batch.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/